Mr. Surendra K. Ajjarapu, Chief Executive Officer Scienture Holdings, Inc. Tampa, FL 33634 Re: SCNX| Placement Agent AgreementPlacement Agent Agreement • September 25th, 2024 • Scienture Holdings, Inc. • Wholesale-drugs, proprietaries & druggists' sundries • New York
Contract Type FiledSeptember 25th, 2024 Company Industry JurisdictionThe purpose of this placement agent agreement (this “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed Regulation A private placement (the “Placement”) by Scienture Holdings, Inc. (collectively, with its Subsidiaries and affiliates, the “Company”) of its Common Stock (the “Securities”). This Agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that Aegis’s obligations hereunder are on a reasonable “best efforts” basis only and that the execution of this Agreement does not constitute a commitment by Aegis to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Aegis with respect to securing any other financing on behalf of the Company. The Company confirms that entry into this Agreement and completion
Fort Lauderdale, Florida 33132 Re: FLGC | Placement Agent AgreementPlacement Agent Agreement • August 7th, 2024 • Flora Growth Corp. • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2024 Company Industry JurisdictionThe purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. ("Aegis") will act as the placement agent on a "best efforts" basis in connection with the proposed private placement (the "Placement") by Flora Growth Corp. (collectively, with its subsidiaries and affiliates, the "Company") of its Common Shares (the "Securities"). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that Aegis's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Aegis to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Aegis with respect to securing any other financing on behalf of the Company. The Company confirms that entry into this placement agent agreement and completion of th
AEGIS CAPITAL CORP.Placement Agent Agreement • December 11th, 2023 • Cyngn Inc. • Services-computer programming services • New York
Contract Type FiledDecember 11th, 2023 Company Industry JurisdictionThe purpose of this placement agent agreement (“Agreement”) Agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed fully marketed public offering (the “Placement”) by Cyngn Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its shares of Common Stock (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • November 14th, 2023 • Cyngn Inc. • Services-computer programming services • New York
Contract Type FiledNovember 14th, 2023 Company Industry JurisdictionThe purpose of this placement agent agreement (“Agreement”) Agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed fully marketed public offering (the “Placement”) by Cyngn Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its shares of Common Stock (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP. July __ 2023Placement Agent Agreement • July 17th, 2023 • Clearmind Medicine Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 17th, 2023 Company Industry JurisdictionThe purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by Clearmind Medicine Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common shares and warrants to purchase common shares (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • April 6th, 2023 • Clearmind Medicine Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 6th, 2023 Company Industry JurisdictionThe purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by Clearmind Medicine Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common shares and warrants to purchase common shares (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Placement Agent Agreement • March 27th, 2023 • Clearmind Medicine Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 27th, 2023 Company Industry JurisdictionThe purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by Clearmind Medicine Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common shares and warrants to purchase common shares (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.